Mice genetically lacking vasoactive intestinal peptide (VIP) unexpectedly developed milder colitis with lower inflammatory markers, challenging the prevailing view that VIP is purely protective in gut inflammation.
Milder colitis without VIPVIP knockout mice showed reduced clinical severity and lower inflammatory cytokines — the opposite of what was predicted for a peptide considered anti-inflammatory.
What the researchers found
When TNBS-induced colitis (a model for Crohn's disease) was triggered in VIP knockout mice, they showed a milder clinical profile compared to wild-type mice. Serum levels of TNF-α and IL-6 were lower in VIP-deficient mice. However, colon histopathological scores and local cytokine levels did not differ between the groups, indicating that VIP's absence selectively disrupted certain but not all immunological compartments.
Interestingly, splenocytes from TNBS-treated VIP knockout mice showed enhanced proliferative responses to T cell stimulation (anti-CD3/CD28), suggesting that while some immune functions were dampened, T cell reactivity was actually increased. This pattern — reduced clinical disease but enhanced T cell responses — mirrors findings in VIP knockout mice with endotoxemia and autoimmune encephalomyelitis.
Why it matters
VIP has been investigated as a potential therapy for inflammatory bowel disease based on decades of research showing it reduces inflammation when injected. This study complicates that narrative by showing that the body's own VIP isn't simply protective — its chronic absence actually makes some aspects of colitis less severe. This is important for anyone developing VIP-based therapies, because the relationship between endogenous VIP signaling and gut inflammation is not the straightforward anti-inflammatory story that was assumed.
The numbers in context
Lower TNF-α and IL-6 in VIP KO mice; enhanced splenocyte proliferative response to anti-CD3/CD28 in VIP KO mice
How the study worked
Researchers administered TNBS (a chemical that induces colitis resembling Crohn's disease) intracolonically to both VIP knockout mice and wild-type controls. They tracked weight loss and disease severity over time, analyzed colon tissue for damage and immune cell infiltration (myeloperoxidase activity), measured TNF-α and IL-6 in both colon tissue and blood, and tested how well spleen immune cells from treated mice responded to T cell stimulation in the lab.
Who was studied
VIP knockout and wild-type C57BL mice
What this study cannot tell us
The study used constitutive VIP knockout mice, meaning VIP was absent from birth. This chronic absence may have caused compensatory changes in the immune system that wouldn't occur with acute VIP manipulation. The TNBS colitis model is a chemical model that doesn't fully replicate human Crohn's disease. Not all parameters showed differences — histopathological scores were similar between groups — suggesting the milder phenotype was selective rather than comprehensive.
How to read the evidence
Rated preliminary: well-controlled knockout mouse study with systematic multi-parameter assessment, but the results are paradoxical and may reflect compensatory changes from lifelong VIP absence rather than the direct role of VIP in colitis.
When this study was published
Published in 2015 in Neuroimmunomodulation. The findings remain relevant to ongoing debates about VIP's therapeutic potential in IBD and the broader complexity of neuropeptide-immune interactions.
The bigger picture
This study is part of a growing body of evidence showing that neuropeptides like VIP have dual roles in immunity — sometimes protective, sometimes harmful, depending on the context. The finding aligns with similar paradoxical results in VIP knockout mice with endotoxemia and autoimmune encephalomyelitis, suggesting that chronic VIP deficiency causes broad immune reprogramming rather than simply removing an anti-inflammatory brake. This has major implications for the development of VIP-based therapeutics for IBD.
Questions still open
- Would acutely blocking VIP in adult mice show the same paradoxical reduction in colitis, or is this effect dependent on lifelong absence?
- How does VIP simultaneously promote and suppress different aspects of the inflammatory response in the gut?
- Should VIP-based IBD therapies be reconsidered given the complex dual role of endogenous VIP in intestinal inflammation?
Common questions
If VIP is anti-inflammatory, why did mice without it have less inflammation?
Does this mean VIP therapy for IBD won't work?
Read the original research
Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis.
Neuroimmunomodulation, 22(3), 203-12
Citation
Abad, Catalina; Cheung-Lau, Gardenia; Coûté-Monvoisin, Anne-Claire; Waschek, James A. (2015). Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis.. Neuroimmunomodulation, 22(3), 203-12. https://doi.org/10.1159/000364912